INDV (Indivior Pharmaceuticals) Other Operating Expense: $-3 Mil (TTM As of Mar. 2026)


INDV Indivior Pharmaceuticals Inc INDV
75 GF Score
Price $40.50
GF Value $22.93
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals Other Operating Expense?

Indivior Pharmaceuticals INDV -1.94% 75 Other Operating Expense is $-3 Mil as of Mar. 2026. GuruFocus rates INDV with a GF Score™ of 75/100 and a GF Value™ of $22.93 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Indivior Pharmaceuticals's Other Operating Expense for the three months ended in Mar. 2026 was $0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-3 Mil.

Indivior Pharmaceuticals's quarterly Other Operating Expense declined from Sep. 2025 ($-1 Mil) to Dec. 2025 ($-2 Mil) but then increased from Dec. 2025 ($-2 Mil) to Mar. 2026 ($0 Mil).

Indivior Pharmaceuticals's annual Other Operating Expense increased from Dec. 2023 ($-9 Mil) to Dec. 2024 ($4 Mil) but then declined from Dec. 2024 ($4 Mil) to Dec. 2025 ($-3 Mil).

Indivior Pharmaceuticals Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Indivior Pharmaceuticals's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior Pharmaceuticals Other Operating Expense Chart

Indivior Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -8.00 -9.00 4.00 -3.00

Indivior Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -1.00 -2.00 0.00
INDV
75GF Score
Indivior Pharmaceuticals Inc INDV
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indivior Pharmaceuticals Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-3 Mil mean?
Indivior Pharmaceuticals (INDV) has a Other Operating Expense of $-3 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Indivior Pharmaceuticals and its competitors.
Is Indivior Pharmaceuticals' Other Operating Expense too high?
Indivior Pharmaceuticals' current Other Operating Expense is $-3 Mil. Overall, Indivior Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' Other Operating Expense compare to KNSA and AMRX?
Indivior Pharmaceuticals' Other Operating Expense of $-3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Indivior Pharmaceuticals and its competitors. Indivior Pharmaceuticals's current Other Operating Expense is $-3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.93, compared to a current price of $40.50 — trading 76.6% above its estimated fair value. The current Other Operating Expense is $-3 Mil. Indivior Pharmaceuticals' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current Other Operating Expense is $-3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of $40.50 is trading 76.6% above its estimated GF Value™ of $22.93. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INDV:

  • Other Operating Expense: $-3 Mil
  • GF Value™: $22.93 vs. price of $40.50 (76.6% above fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Indivior Pharmaceuticals Business Description

Other Exchanges E7P:Germany
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
75GF Score

Get the complete analysis for INDV

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$40.50
Price
$22.93
GF Value